Tisotumab vedotin (Tivdak) for cervical cancer.

Med Lett Drugs Ther ; 66(1705): e109-e110, 2024 Jun 24.

Article in En | MEDLINE | ID: mdl-38905529

Subject(s)

Uterine Cervical Neoplasms; Humans; Female; Uterine Cervical Neoplasms/drug therapy; Antibodies, Monoclonal, Humanized/therapeutic use; Antibodies, Monoclonal, Humanized/adverse effects; Antineoplastic Agents, Immunological/adverse effects; Antineoplastic Agents, Immunological/therapeutic use

Key words

Tivdak; adverse effects; cervical cancer; dosage; drug interactions; efficacy; gemcitabine; irinotecan; lactation; permetrexed; pregnancy; safety; tisotumab vedotin; topotecan; vinorelbine

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uterine Cervical Neoplasms Limits: Female / Humans Language: En Journal: Med Lett Drugs Ther Year: 2024 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google